Clinical Study

Swog S1806 Phase III Randomized Trial Of Concurrent Chemoradiotherapy With Or Without Atezolizumab In Localized Muscle Invasive Bladder Cancer

Posted Date: May 22, 2020

  • Investigator: Robert Franklin
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The primary goal of this study is to compare bladder intact event-free survival (BI-EFS) for concurrent chemoradiation therapy (CRT) with and without atezolizumab in localized muscle invasive bladder cancer (MIBC)

Criteria:

To Be Eligible: Must Have Urothelial Carcinoma Of The Bladder, Undergo Radiological Staging Within 70 Days, Zubrod Performance Status = 2, No Prior Malignancy Except Non-Melanoma Skin Cancer, No Systemic Chemotherapy For Bladder Cancer, No Major Surgery Within 28 Days,

Keywords:

Bladder Cancer, Chemoradiotherapy

For More Information:

Uc Cancer Center
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.